Super Micro executives sound upbeat — but the stock is still a sell, analyst says

Super Micro’s management helped assuage some concerns over customer orders, margins and liquidity, but J.P. Morgan is still bearish on the stock.

Topics

Cigna’s stock leads selloff among drug middlemen on breakup fears — but this analyst says it’s not a real risk

One influential healthcare analyst says the chances of such a bill passing are less than 5%.
MarketWatch - 5h
C3.ai is still ‘extremely unprofitable’ so don’t buy the stock, analyst says

C3’s stock bounced back, but J.P. Morgan has a price target that implies a 35% downside.
MarketWatch - 1d
Super Micro’s stock still faces accounting overhang despite delisting reprieve

Super Micro’s stock rallies after Nasdaq extends the deadline for financial filings, but the stock is still being weighed down by an accounting overhang.
MarketWatch - 2d
Super Micro gets Nasdaq listing extension, says it can file financials by February

Super Micro said it received a letter from Nasdaq informing the company of the extension to stay listed.
CNBC - 5d
Amazon has caught up in the AI race, analysts say, and its stock surges to another record

Amazon’s stock was heading for a third straight record close Friday, as the company’s AWS re:Invent conference gave analysts reason to believe it has caught up with its AI rivals.
MarketWatch - 5d
Ulta Beauty’s stock on track for biggest gain in 2 years. One analyst says it’s still undervalued.

Beauty and cosmetics company’s latest earnings cheered investors and at least 17 analysts hiked stock price targets.
MarketWatch - 5d
Lululemon’s stock soars as 16 banks hike their price targets. One bear says sell into the rally.

The athleisure-apparel company’s pivot to bright colors seems to be working.
MarketWatch - 5d
Why Foot Locker’s stock is sliding despite upbeat Thanksgiving-week sales

The company is dealing with “softer consumer demand outside of key selling periods,” as well as the need for more promotions.
MarketWatch - Dec. 4

Super Micro executives sound upbeat — but the stock is still a sell, analyst says

Topics

Related

Cigna’s stock leads selloff among drug middlemen on breakup fears — but this analyst says it’s not a real risk

C3.ai is still ‘extremely unprofitable’ so don’t buy the stock, analyst says

Super Micro’s stock still faces accounting overhang despite delisting reprieve

Super Micro gets Nasdaq listing extension, says it can file financials by February

Amazon has caught up in the AI race, analysts say, and its stock surges to another record

Ulta Beauty’s stock on track for biggest gain in 2 years. One analyst says it’s still undervalued.

Lululemon’s stock soars as 16 banks hike their price targets. One bear says sell into the rally.

Why Foot Locker’s stock is sliding despite upbeat Thanksgiving-week sales

More from MarketWatch

UnitedHealthcare exec’s murder exposes a deeper problem no one wants to face

I’m 42 and married with no kids. I have $114K in a 401(k) and $1,400 in credit-card debt. How can I grow my wealth?

I have two life-insurance policies, but ‘rude’ agents keep calling me to change the terms. How do I stop this harassment?

‘I take pride in being debt-free’: My husband owes thousands of dollars in student loans and credit-card debt. Will I be on the hook if he dies?

Here’s what to make of Trump’s promise of expedited permits for big investments